

wherein:

A1
cont.
R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of C₁ to C₂₀, and


W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof; and

a pharmaceutically acceptable carrier, diluent, or excipient.

✓
Add the following new claims:

70. A pharmaceutical composition, comprising a first amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



wherein:


R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length greater than C₆, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof, and

a pharmaceutically acceptable carrier, diluent, or excipient.

71. A pharmaceutical composition, comprising a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



wherein:


R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length of between C₆ and C₁₂, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and mixtures thereof, and

a pharmaceutically acceptable carrier, diluent, or excipient.

72. A pharmaceutical composition, comprising a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



wherein:


R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length greater than C₆, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate; and

a pharmaceutically acceptable carrier, diluent, or excipient.

73. A pharmaceutical composition, comprising a first amount of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



wherein:

R is selected from the group consisting of arylalkyl, cycloalkylalkyl, and branched or straight chain alkyl having a chain length greater than C₆, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a second amount of an antiviral compound selected from the group consisting of

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine,

(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC),

(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC),

(-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC],

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC),

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP)

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluarcil (FMAU),

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide,

2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt),

2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt),

2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt),

2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt),

2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt),

2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt),

2',3'-dideoxy-3'-fluorothymidine (FddThd),

2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC),

2',3'-dideoxy-beta-L-5-thiacytidine,

2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC),

2'-deoxy-3'-thia-5-fluorocytosine,

3'-amino-5-methyl-dexocytidine (AddMeCyt),

3'-chloro-5-methyl-dexocytidine (ClddMeCyt),

9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside,

9-(2-phosphonylmethoxyethyl)adenine (PMEA),

acyclovir triphosphate (ACVTP),

D-carbocyclic-2'-deoxyguanosine (CdG),

dideoxy-cytidine,

dideoxy-cytosine (ddC),

dideoxy-guanine (ddG),

dideoxy-inosine (ddI),

E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate,

fluoro-arabinofuranosyl-iodouracil,

stavudine,

A2
cont.
2-deoxy-3'-thia-5-fluorocytidine,

2',3'-dideoxy-guanine, and

2',3'-dideoxy-guanosine; and

a pharmaceutically acceptable carrier, diluent, or
excipient.
